MGC Pharmaceuticals   Report issue

For profit Phase 2 Phase 3
Founded: Perth Australia (2005)

Organization Overview

First Clinical Trial
2020
NCT04382040
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

MGC Pharmaceuticals | MGC Pharmaceuticals d.o.o | MGC Pharmacuticals

Active Ingredients

Drugs in Phase 3 Trials (4)

artemisinin (2 trials)

boswellia serrata (1 trial)

curcumin (1 trial)

vitamin c (1 trial)

Drugs in Phase 2 Trials (1)

cannabis (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Communicable Diseases (Phase 2)

Coronavirus Infections (Phase 2)

Drug Resistant Epilepsy (Phase 2)

Epilepsy (Phase 2)

Infections (Phase 2)

Severe Acute Respiratory Syndrome (Phase 2)

Virus Diseases (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 5